谢慧,姜顺军,陈文瑛,肖翔林,喻鹏久
XIE Hui,JIANG Shunjun,CHEN Wenying,XIAO Xianglin,YU Pengjiu

• 1:广州医科大学附属第一医院药学部

摘要(Abstract)：

目的研究己烯雌酚对大鼠肝微粒体中细胞色素P450同工酶2C6(CYP2C6)和2D2(CYP2D2)的抑制作用。方法采用探针底物法,使用液相色谱-串联质谱检测在不同浓度的己烯雌酚孵育体系中,CYP2C6和CYP2D2的特征性底物双氯芬酸与右美沙芬产生的代谢产物4’-羟基双氯芬酸与右啡烷的浓度。计算得到己烯雌酚对CYP2C6与CYP2D2的半数抑制浓度(IC50)。结果己烯雌酚对大鼠CYP2C6与CYP2D2的IC50值分别为(5.31±0.06)μmol/L,(7.03±0.01)μmol/L。结论己烯雌酚对大鼠CYP2C6与CYP2D2具有中等抑制作用,有必要进一步在体外人体水平对其进行评价以预防潜在的临床药物相互作用。
OBJECTIVE To evaluate the inhibition effect of diethylstilbestrol on CYP2C6 and CYP2D2 in rat liver microsomes.METHODS By adoption of probe substrate method,high performance liquid chromatography-tandem mass spectrometry was used to quantify the metabolites( 4 '-hydroxydiclofenac and dextorphan) of the probe substrates( diclofenac and dextromethorphan) for CYP2C6 and CYP2D2 respectively under different diethylstilbestrol levels. The half inhibition concentrations( IC50) were then calculated. RESULTS The IC50 of diethylstilbestrol on CYP2C6 and CYP2D2 were( 5. 31 ± 0. 06) μmol / L and( 7. 03 ± 0. 01) μmol /L,respectively. CONCLUSION Diethylstilbestrol exhibited a moderate inhibition effect on rat CYP2C6 and CYP2D2. Further in vitro evaluation at human level is needed to avoid any potential clinical drug-drug interaction.

关键词(KeyWords)： 己烯雌酚;药物相互作用;大鼠肝微粒体
diethylstilbestrol;drug-drug interaction;rat liver microsomes

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 谢慧,姜顺军,陈文瑛,肖翔林,喻鹏久
XIE Hui,JIANG Shunjun,CHEN Wenying,XIAO Xianglin,YU Pengjiu

参考文献(References)：

• [1]Turo R,Smolski M,Esler R,et al.Diethylstilboestrol for the treatment of prostate cancer:past,present and future[J].Scand J Urol,2014,48(1):4-14.
• [2]Peethambaram PP,Ingle JN,Suman VJ,et al.Randomized trial of diethylstilbestrol vs.tamoxifen in postmenopausal women with metastatic breast cancer.An updated analysis[J].Breast Cancer Res Treat,1999,54(2):117-122.
• [3]Shamash J,Powles T,Sarker SJ,et al.A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer:immediate vs deferred Diethylstilbestrol[J].Br J Cancer,2011,104(4):620-628.
• [4]Mc Donnell AM,Dang CH.Basic review of the cytochrome p450 system[J].J Adv Pract Oncol,2013,4(4):263-8.
• [5]Pandey AV,Flück CE.NADPH P450 oxidoreductase:structure,function,and pathology of diseases[J].Pharmacol Ther,2013,138(2):229-54.
• [6]曲衍清,梁锐,孙德光,等.己烯雌酚对人肝微粒体内CYP3A4和CYP2C9酶的抑制作用[J].中国药理学与毒理学杂志,2011,25(2):170-176.
• [7]Qu YQ,Fang ZZ,Yang L,et al.Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol[J].Pharmazie,2011,66:216-221.
• [8]Bjornsson TD,Callaghan JT,Einolf HJ,et al.The conduct of in vitro and in vivo drug-drug interaction studies:a Pharmaceutical Research and Manufacturers of America(Ph RMA)perspective[J].Drug Metab Dispos,2003,31(7):815-832.
• [9]Zhang T,Zhu Y,Gunaratna C.Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry[J].J Chromatogr B Analyt Technol Biomed Life Sci,2002,780(2):371-379.
• [10]Yan Z,Caldwell GW.The current status of time dependent CYP inhibition assay and in silico drug-drug interaction predictions[J].Curr Top Med Chem,2012,12(11):1291-127.